The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Stankovich Thomas since 2009.
This trader's CIK number is 1181166.
At the time of last reporting, Stankovich Thomas was the Chief Financial Officer of Reshape Lifesciences Inc.. (stock ticker symbol RSLS).
Also see all insider trading activities at Reshape Lifesciences Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | RSLS | 4,635 | $13,905 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2009 | RGDX | 7,000 | $9,661 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | RSLS | 0 | $0 | 172 | $37 | 0 | $0 |
| 2023 | RSLS | 17,702 | $26,907 | 1,262 | $4,991 | 0 | $0 |
| 2022 | RSLS | 20,000 | $18,200 | 427,543 | $101,872 | 0 | $0 |
| 2021 | RSLS | 50,000 | $140,120 | 60,650 | $169,361 | 0 | $0 |
1. Reshape Lifesciences Inc. (RSLS)
2. Response Genetics Inc (RGDX)
3. Reshape Lifesciences Inc. (RSLS)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-09-16 | RSLS | Buy | 530 | 3.00 | 1,590 |
| 2020-08-19 | RSLS | Buy | 4,105 | 3.00 | 12,315 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2009-12-14 | RGDX | Buy | 1,000 | 1.24 | 1,235 |
| 2009-12-10 | RGDX | Buy | 4,000 | 1.39 | 5,560 |
| 2009-12-11 | RGDX | Buy | 2,000 | 1.43 | 2,866 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-11-30 | RSLS | Sale | 39 | .23 | 8 |
| 2023-12-31 | RSLS | Sale | 42 | .25 | 10 |
| 2024-05-31 | RSLS | Sale | 48 | .25 | 12 |
| 2024-02-29 | RSLS | Sale | 43 | .17 | 7 |
| 2023-10-25 | RSLS | Sale | 131 | .27 | 35 |
| 2023-09-01 | RSLS | Sale | 118 | .89 | 105 |
| 2023-08-04 | RSLS | Sale | 108 | 1.43 | 154 |
| 2023-10-11 | RSLS | Sale | 39 | .93 | 36 |
| 2023-08-24 | RSLS | Sale | 39 | 1.42 | 55 |
| 2023-07-06 | RSLS | Sale | 106 | 1.47 | 155 |
| 2023-05-31 | RSLS | Sale | 98 | 2.41 | 236 |
| 2023-04-30 | RSLS | Sale | 96 | 2.36 | 226 |
| 2023-03-31 | RSLS | Sale | 109 | 2.60 | 283 |
| 2023-06-30 | RSLS | Buy | 17,702 | 1.52 | 26,907 |
| 2023-01-24 | RSLS | Sale | 158 | 7.49 | 1,183 |
| 2023-02-02 | RSLS | Sale | 157 | 13.29 | 2,086 |
| 2023-02-28 | RSLS | Sale | 103 | 4.25 | 437 |
| 2022-11-28 | RSLS | Sale | 364,756 | .17 | 62,008 |
| 2022-12-01 | RSLS | Sale | 7,357 | .15 | 1,110 |
| 2022-11-04 | RSLS | Sale | 8,393 | .27 | 2,282 |
| 2022-10-04 | RSLS | Sale | 8,293 | .28 | 2,330 |
| 2022-09-06 | RSLS | Sale | 4,828 | .39 | 1,882 |
| 2022-08-05 | RSLS | Sale | 4,728 | .47 | 2,222 |
| 2022-07-01 | RSLS | Sale | 4,630 | .55 | 2,546 |
| 2022-06-01 | RSLS | Sale | 4,478 | .96 | 4,298 |
| 2022-05-31 | RSLS | Buy | 20,000 | .91 | 18,200 |
| 2022-05-05 | RSLS | Sale | 4,529 | .77 | 3,487 |
| 2022-04-01 | RSLS | Sale | 5,038 | 1.13 | 5,692 |
| 2022-02-28 | RSLS | Sale | 3,658 | 1.06 | 3,877 |
| 2022-01-31 | RSLS | Sale | 3,684 | 1.22 | 4,494 |
| 2022-01-04 | RSLS | Sale | 3,171 | 1.78 | 5,644 |
| 2021-12-02 | RSLS | Sale | 4,304 | 1.83 | 7,863 |
| 2021-11-18 | RSLS | Buy | 20,000 | 2.02 | 40,400 |
| 2021-11-02 | RSLS | Sale | 4,320 | 2.69 | 11,620 |
| 2021-10-01 | RSLS | Sale | 3,660 | 2.76 | 10,101 |
| 2021-09-10 | RSLS | Sale | 48,366 | 2.89 | 139,777 |
| 2021-08-30 | RSLS | Buy | 15,000 | 3.43 | 51,435 |
| 2021-08-20 | RSLS | Buy | 15,000 | 3.22 | 48,285 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Stankovich Thomas (Chief Financial Officer of Reshape Lifesciences Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.